Hypothesis

Senescent cells function not only as signal broadcasters but also as extracellular sinks that sequester key growth factors (e.g., IGF‑1, TGF‑β, PDGF‑AA) through upregulated binding proteins and matrix‑modifying enzymes. Their transient presence creates a localized depletion zone that restrains neighboring stem and progenitor cell proliferation, thereby preventing runaway expansion in damaged or premalignant tissue. When senescent cells accumulate beyond immune clearance capacity, the sink becomes saturated, and the sequestered factors are released in a burst, driving fibrosis or tumorigenesis. Senolytic clearance therefore resolves one problem (inflammatory SASP) while potentially detonating another (unrestrained growth‑factor signaling).

Mechanistic Basis

1. Sequestration machinery – Senescent fibroblasts markedly increase expression of IGF‑binding proteins (IGFBP‑3, IGFBP‑5) and matricellular proteins such as decorin and fibronectin‑extra domain A, which bind IGF‑1, TGF‑β and PDGF‑AA with high affinity (source).
2. Matrix‑bound reservoirs – Senescence‑associated metalloproteinases (MMP‑3, MMP‑9) cleave extracellular matrix components, exposing cryptic binding sites that trap growth factors (source).
3. Dynamic release threshold – Mathematical modeling of sink capacity predicts a critical senescent cell density (~5‑10% of stromal cells) beyond which binding sites become occupied and subsequent apoptotic clearance releases the stored ligand pool in a bolus (source).
4. Feedback to SASP – Sequestration reduces local ligand availability, dampening autocrine SASP amplification; loss of the sink lifts this brake, converting an early‑phase reparative SASP into a chronic, pro‑fibrotic profile via NF‑κB/cGAS‑STING (source).

Testable Predictions

• Prediction 1: In young mouse skin, inducible p16‑positive senescent fibroblasts will show elevated IGFBP‑5 and decorin expression; concomitant immunofluorescence will reveal reduced free IGF‑1 and TGF‑β in the interstitial space compared with senescent‑cell‑deficient controls.
• Prediction 2: Pharmacological senolysis (dasatinib + quercetin) in this model will cause a transient spike (>2‑fold) in bioavailable IGF‑1/TGF‑β measured by ELISA of wound exudate, preceding increased collagen deposition and α‑SMA‑positive myofibroblast accumulation at day 7 post‑injury.
• Prediction 3: Genetic overexpression of IGFBP‑5 specifically in senescent cells will attenuate the post‑senolytic surge in growth‑factor activity and mitigate fibrosis, whereas IGFBP‑5 knockdown will exacerbate it even without senolytics.
• Prediction 4: In a premalignant epidermal model (Kras^G12D; p53^−/^), senescent cell clearance will accelerate tumor onset only when IGFBP‑5 is concurrently knocked down, indicating that sink loss enables oncogenic growth‑factor signaling.

Potential Implications

If validated, this hypothesis reframes senolytics from simple ‘kill‑switch’ tools to interventions that must be temporally paired with growth‑factor buffering strategies (e.g., IGFBP‑mimetic peptides or decorin‑based hydrogels). It also explains tissue‑specific outcomes of senolytic trials: organs with high basal IGF‑1/TGF‑β turnover (lung, liver) may experience adverse proliferative bursts, whereas low‑turnover tissues (brain, cartilage) could benefit. Ultimately, treating senescence as a dynamic nutrient‑sink rather than a static source of harm opens a combinatorial therapeutic window where clearance is coupled with transient sequestration to preserve the hostage‑negotiation balance.

• IGFBP‑5 decorin sequestration model (source)
• MMP‑mediated matrix binding (source)
• Senolytic dasatinib + quercetin (source)
• Early SASP immune recruitment (source)